Ultragenyx Pharmaceutical (RARE) to Release Quarterly Earnings on Thursday

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) will release its earnings data after the market closes on Thursday, May 2nd. Analysts expect Ultragenyx Pharmaceutical to post earnings of ($1.73) per share for the quarter. Persons that wish to listen to the company's earnings conference call can do so using this link.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported ($1.52) earnings per share for the quarter, topping the consensus estimate of ($1.65) by $0.13. The firm had revenue of $127.39 million during the quarter, compared to analysts' expectations of $119.38 million. Ultragenyx Pharmaceutical had a negative return on equity of 369.54% and a negative net margin of 139.70%. The company's quarterly revenue was up 23.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($2.16) EPS. On average, analysts expect Ultragenyx Pharmaceutical to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ:RARE traded up $0.39 on Friday, hitting $44.24. 450,422 shares of the stock were exchanged, compared to its average volume of 754,900. The stock has a market capitalization of $3.64 billion, a price-to-earnings ratio of -5.29 and a beta of 0.65. Ultragenyx Pharmaceutical has a 52 week low of $31.52 and a 52 week high of $54.98. The company's 50-day moving average price is $47.89 and its 200 day moving average price is $43.75.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, EVP Thomas Richard Kassberg sold 11,509 shares of the company's stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $49.93, for a total transaction of $574,644.37. Following the completion of the transaction, the executive vice president now owns 252,823 shares of the company's stock, valued at approximately $12,623,452.39. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Ultragenyx Pharmaceutical news, EVP Thomas Richard Kassberg sold 11,509 shares of the company's stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $49.93, for a total transaction of $574,644.37. Following the completion of the transaction, the executive vice president now owns 252,823 shares of the company's stock, valued at approximately $12,623,452.39. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider John Richard Pinion sold 4,173 shares of the company's stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $53.76, for a total value of $224,340.48. Following the transaction, the insider now directly owns 89,268 shares of the company's stock, valued at approximately $4,799,047.68. The disclosure for this sale can be found here. Insiders sold a total of 32,116 shares of company stock valued at $1,645,983 in the last quarter. 6.80% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages have weighed in on RARE. JPMorgan Chase & Co. boosted their price objective on Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the stock an "overweight" rating in a report on Monday, March 18th. Wedbush reaffirmed a "neutral" rating and issued a $48.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, April 16th. Royal Bank of Canada assumed coverage on Ultragenyx Pharmaceutical in a research note on Monday. They issued an "outperform" rating and a $77.00 price target for the company. Robert W. Baird upped their price target on Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the company an "outperform" rating in a research note on Tuesday, January 30th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $107.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, April 5th. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $88.08.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.